Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
GLSI
Upturn stock ratingUpturn stock rating

Greenwich Lifesciences Inc (GLSI)

Upturn stock ratingUpturn stock rating
$9.07
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: GLSI (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $39

1 Year Target Price $39

Analysts Price Target For last 52 week
$39Target price
Low$8.06
Current$9.07
high$17.49

Analysis of Past Performance

Type Stock
Historic Profit -28.52%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 120.18M USD
Price to earnings Ratio -
1Y Target Price 39
Price to earnings Ratio -
1Y Target Price 39
Volume (30-day avg) 1
Beta 3.25
52 Weeks Range 8.06 - 17.49
Updated Date 06/30/2025
52 Weeks Range 8.06 - 17.49
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.27

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -253.55%
Return on Equity (TTM) -515.27%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 117297410
Price to Sales(TTM) -
Enterprise Value 117297410
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -21.23
Shares Outstanding 13368300
Shares Floating 6112523
Shares Outstanding 13368300
Shares Floating 6112523
Percent Insiders 52.3
Percent Institutions 9.47

Analyst Ratings

Rating 1
Target Price 39
Buy 1
Strong Buy -
Buy 1
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Greenwich Lifesciences Inc

stock logo

Company Overview

overview logo History and Background

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences. Founded to address unmet needs in breast cancer treatment, the company has primarily focused on advancing its GP2 clinical program.

business area logo Core Business Areas

  • GP2 Immunotherapy Development: The core business focuses on the development and clinical trials of GP2, a HER2/neu peptide designed to stimulate the patient's immune system to target and destroy residual cancer cells, potentially preventing recurrence in HER2/neu positive breast cancer patients.

leadership logo Leadership and Structure

Greenwich LifeSciences is led by a management team with experience in biotechnology and clinical development. The company structure is typical of a small, clinical-stage biotech, with emphasis on research, clinical operations, and regulatory affairs.

Top Products and Market Share

overview logo Key Offerings

  • GP2: GP2 is Greenwich LifeSciences' lead product candidate, an immunotherapy designed to prevent breast cancer recurrence. It is currently in Phase III clinical trials. Market share data is not applicable as the product is not yet approved for commercial sale. Competitors include companies developing other breast cancer therapies, such as Roche/Genentech (Herceptin, Perjeta, Kadcyla), and Puma Biotechnology (Nerlynx). Once approved, GP2 would compete in the adjuvant breast cancer treatment market.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive, with significant R&D investment and stringent regulatory oversight. The breast cancer therapeutics market is substantial and growing, driven by increased incidence and improved diagnosis. The focus is on targeted therapies and immunotherapies.

Positioning

Greenwich LifeSciences aims to position GP2 as a novel immunotherapy for preventing breast cancer recurrence. Its competitive advantage, if clinical trials are successful, would be offering a new approach compared to standard treatments. It is a relatively small company seeking to disrupt the existing adjuvant treatment landscape.

Total Addressable Market (TAM)

The total addressable market for adjuvant breast cancer therapies is significant, estimated in the billions of dollars annually. Greenwich LifeSciences is positioned to capture a portion of this market with GP2, if approved, targeting HER2/neu positive patients post-surgery. The TAM can be estimated using annual cancer diagnoses and prevalence rates.

Upturn SWOT Analysis

Strengths

  • Novel immunotherapy approach
  • Potential to address unmet need in preventing breast cancer recurrence
  • Focused development of GP2

Weaknesses

  • Reliance on a single product candidate (GP2)
  • Limited financial resources compared to larger pharmaceutical companies
  • Clinical trial risk and regulatory hurdles

Opportunities

  • Successful completion of Phase III clinical trials
  • Partnership with larger pharmaceutical companies
  • Expansion of GP2's application to other HER2/neu expressing cancers

Threats

  • Clinical trial failure
  • Regulatory disapproval
  • Competition from existing and emerging therapies
  • Inability to secure sufficient funding

Competitors and Market Share

competitor logo Key Competitors

  • ROCHE (ROG.SW)
  • PBYI (PBYI)

Competitive Landscape

Greenwich LifeSciences is a small player competing against larger pharmaceutical companies with established breast cancer therapies. Its advantage lies in its novel immunotherapy approach, but faces challenges in terms of resources and market access.

Growth Trajectory and Initiatives

Historical Growth: Greenwich LifeSciences' growth is tied to the progress of GP2 through clinical trials. The company has shown growth potential contingent on successful clinical data.

Future Projections: Future growth depends on the successful commercialization of GP2. Analyst projections are based on estimated market penetration and pricing assumptions.

Recent Initiatives: Recent initiatives include advancing the Phase III clinical trial of GP2 and seeking potential partnerships.

Summary

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focusing on GP2, a novel immunotherapy for breast cancer recurrence prevention. The company's strength lies in its innovative approach, but it faces significant risks associated with clinical trials and competition from established therapies. Success hinges on positive Phase III trial results and securing adequate funding for commercialization. It needs to look out for potential trial failures and ensure sufficient capital to operate.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings (SEC)
  • Industry reports
  • Analyst reports

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share is estimated and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Greenwich Lifesciences Inc

Exchange NASDAQ
Headquaters Stafford, TX, United States
IPO Launch date 2020-09-25
CEO, CFO & Director Mr. Snehal S. Patel
Sector Healthcare
Industry Biotechnology
Full time employees 4
Full time employees 4

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.